Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Gray

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Neurobiology of Disease|November 22, 2020
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human diseaseDavid J Marmion, Angela A Rutkowski, Diptaman Chatterjee, et al.
Gene Therapy|December 22, 2023
CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsyEmrah Gumusgoz, Sahba Kasiri, Mayank Verma, et al.
Molecular Therapy. Methods & Clinical Development|May 13, 2017
Improved <i>MECP2</i> Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal DeliverySarah E Sinnett, Ralph D Hector, Kamal K E Gadalla, et al.
Human Gene Therapy|May 21, 2016
Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff MiceKarlaina J L Osmon, Evan Woodley, Patrick Thompson, et al.
Frontiers in Pharmacology|November 9, 2023
Efficacy of dual intracerebroventricular and intravitreal <i>CLN5</i> gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten diseaseSamantha J Murray, Martin P Wellby, Graham K Barrell, et al.
International Journal of Molecular Sciences|July 2, 2021
Investigating Immune Responses to the scAAV9-<i>HEXM</i> Gene Therapy Treatment in Tay-Sachs Disease and Sandhoff Disease Mouse ModelsShalini Kot, Subha Karumuthil-Melethil, Evan Woodley, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formationEsther O Alao, Mehrnaz Sheibani, Jun Wu, et al.
Human Gene Therapy|May 21, 2016
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs DiseaseSubha Karumuthil-Melethil, Sahana Nagabhushan Kalburgi, Patrick Thompson, et al.
Plos One|June 7, 2018
Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.
Plos One|November 2, 2018
Correction: Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Neurobiology of Disease|November 22, 2020
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human diseaseDavid J Marmion, Angela A Rutkowski, Diptaman Chatterjee, et al.
Gene Therapy|December 22, 2023
CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsyEmrah Gumusgoz, Sahba Kasiri, Mayank Verma, et al.
Molecular Therapy. Methods & Clinical Development|May 13, 2017
Improved <i>MECP2</i> Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal DeliverySarah E Sinnett, Ralph D Hector, Kamal K E Gadalla, et al.
Human Gene Therapy|May 21, 2016
Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff MiceKarlaina J L Osmon, Evan Woodley, Patrick Thompson, et al.
Frontiers in Pharmacology|November 9, 2023
Efficacy of dual intracerebroventricular and intravitreal <i>CLN5</i> gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten diseaseSamantha J Murray, Martin P Wellby, Graham K Barrell, et al.
International Journal of Molecular Sciences|July 2, 2021
Investigating Immune Responses to the scAAV9-<i>HEXM</i> Gene Therapy Treatment in Tay-Sachs Disease and Sandhoff Disease Mouse ModelsShalini Kot, Subha Karumuthil-Melethil, Evan Woodley, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formationEsther O Alao, Mehrnaz Sheibani, Jun Wu, et al.
Human Gene Therapy|May 21, 2016
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs DiseaseSubha Karumuthil-Melethil, Sahana Nagabhushan Kalburgi, Patrick Thompson, et al.
Plos One|June 7, 2018
Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.
Plos One|November 2, 2018
Correction: Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.
Pageof 11